XRTX Key Statistics, Chart & Performance
The current stock price of XRTX is 0.6484 USD. In the past month the price increased by 3.1%. In the past year, price decreased by -48.94%.
XRTX Latest News, Press Relases and Analysis
XRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About XRTX
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
XORTX THERAPEUTICS INC / XRTX FAQ
What does XORTX THERAPEUTICS INC do?
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
What is the current price of XRTX stock?
The current stock price of XRTX is 0.6484 USD. The price increased by 4.08% in the last trading session.
Does XRTX stock pay dividends?
XRTX does not pay a dividend.
What is the ChartMill rating of XORTX THERAPEUTICS INC stock?
XRTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of XORTX THERAPEUTICS INC (XRTX) based on its PE ratio?
XORTX THERAPEUTICS INC (XRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
What is XORTX THERAPEUTICS INC worth?
XORTX THERAPEUTICS INC (XRTX) has a market capitalization of 4.51M USD. This makes XRTX a Nano Cap stock.
XRTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XRTX. When comparing the yearly performance of all stocks, XRTX is a bad performer in the overall market: 90.97% of all stocks are doing better.
XRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XRTX. While XRTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
XRTX Financial Highlights
Over the last trailing twelve months XRTX reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -1213.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -98.46% | ||
| Debt/Equity | 0 |